Form 4: Phreesia SVP David Linetsky Sells Shares Under 10b5-1 Trading Plan

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 11,616 shares of common stock at an average price of $29.7005 per share under a pre-arranged 10b5-1 trading plan.

Summary

• David Linetsky, SVP of Life Sciences at Phreesia, Inc., reported a transaction involving the sale of Phreesia's common stock.
• The transaction occurred on February 13, 2025.
• Mr. Linetsky sold 11,616 shares at a weighted average price of $29.7005 per share.
• The sales were executed under a Rule 10b5-1 trading plan adopted on July 18, 2024.
• Following the transaction, Mr. Linetsky directly owns 218,135 shares of Phreesia's common stock.
• Additionally, he indirectly owns 8,851 shares through his spouse.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a standard Form 4 filing for an insider stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of an insider stock sale. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The sale itself doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The stock sale by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Phreesia, David Linetsky, Form 4, insider trading, stock sale, 10b5-1 plan, PHR, SVP Life Sciences